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SUMMARY Granulocyte lysosomal enzymes can potentially participate in cartilage degradation in
inflammatory arthritides. However, we have previously shown that the quantity of several such
enzymes in an inflammatory synovial effusion correlates negatively with the degree of radio-
graphic damage of the joint from which the fluid was sampled. In the current work the quantity
of the following 5 protease inhibitors was determined immunochemically in the same fluids: al
antitrypsin, aoc-antichymotrypsin, M2-macroglobulin, inter-a-trypsin inhibitor, and Cl esterase
inhibitor. These inhibitors are generally covariate and correlate positively with the total protein
in the fluid as well as the number of granulocytes and the concentration of granulocyte lysosomal
enzymes in the fluid. As did the lysosomal enzymes, the protease inhibitors correlate negatively with
radiographic destruction. It is likely that lysosomal enzymes in solution in inflammatory synovial
effusions are rendered effete by the presence of protease inhibitors.
One theory of the pathogenesis of articular destruc-
tion in rheumatoid arthritis holds that polymor-
phonuclear neutrophil (PML) lysosomal enzymes in
solution in the inflammatory synovial fluid are
primarily responsible for cartilage degradation.' If
this were so, one would predict that the quantity of
activePML lysosomal enzymes in synovial fluid would
correlate with the degree of joint destruction. In a
recent study2 we have tested this corollary hypo-
thesis. By 9 immunochemical and enzymatic assays
we quantitated 5 different granulocytic enzymes in
synovial fluids from 36 patients. We are sampling a
single point in time in a spectrum of disease with
considerable chronicity and variability. Nonetheless
a population of this size allows us to test a null
hypothesis (an absence of correlation between the
quantity of enzymes and the degree of radiographic
destruction of the joint sampled) with some con-
fidence. We were able to reject this null hypothesis-
but the correlation we observed was negative. In
other words, the greater the quantity of enzymes we
detected, the less likely was the fluid sampled from a
radiographically damaged joint.
This unexpected result raises 2 important ques-
tions: Since human lysosomal enzymes have the
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potential to participate in cartilage destruction,37
why are the enzymes in the fluid effete? And granted
these enzymes are effete, why are they inversely
related to destruction rather than simply unrelated?
This second question provides impetus to consider-
able speculation. However, one potential answer to
the first question is quite apparent: protease inhibi-
tors present in the same fluids render the enzymes
ineffective. Testing this hypothesis is the subject
of the current report.
Normal human plasma contains at least 9 in-
hibitors of proteolytic enzymes 89. All these protease
inhibitors are synthesised in the liver, and most,
particularly ocl-antitrypsin and xl-antichymotrypsin,
are acute-phase reactants. Vascular, pulmonary,
hepatic, and immunological diseases are associated
with genetic deficiencies of several of these inhibitors.
In view of the morbidity associated with their
absence, a major role for protease inhibitors is
postulated in normal homoeostasis. Most of the
protease inhibitors combine with the target enzyme
rendering the enzyme inactive or altering the sub-
strate specificity. The latter appears to be the case
for x2-macroglobulin, where enzyme-inhibitor com-
plexes can still hydrolyse low-molecular-weight
substrates.10 In order to function to bind and inhibit
a protease, most inhibitors are first substrates of the
protease they inhibit, that is, limited specific proteo-
lysis of the inhibitor is prequisite to binding.11 12
In the current study we employed highly specific
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electroimmunoassays to measure 5 protease inhibi-
tors. We assayed the same pathological synovial
fluids that were studied previously for their content
of lysosomal enzymes.2
Materials and methods
PATIENTS AND SYNOVIAL FLUID
COLLECTION
The same synovial fluid samples used in the earlier
study of lysosomal enzyme content2 were used in the
current study. These had been collected at the time
of a clinically indicated diagnostic arthrocentesis.
All fluids were obtained from the knee with the
exception of one olecranon bursal aspirate. No
patient had a fixed deformity of the knee that
precluded ambulation. All patients were taking
nonsteroidal anti-inflammatory agents, 2 prednisone
in low doses, and 5 were receiving gold salt therapy.
The drug regimen did not influence the results of the
data analyses.
At the time of arthrocentesis an aliquot was
collected in EDTA (3 mg/10 ml) and the total
leucocyte count and differential recorded. The
remainder was not anticoagulated but was clarified
by centrifugation within hours of sampling. Another
aliquot was analysed for total protein (TP) and
C3.13 The remainder was frozen in small aliquots
at -200C and thawed prior to enzyme assay.
Thirty-two synovial fluids were tested from 31
patients.
X-rays were available of 27 of the aspirated knees.
These were taken in close temporal proximity to the
arthrocentesis. The films were scored from 0 to 4 in
accordance with the degree of destruction as in
previous studies.2 This scoring was performed
without access to diagnosis or results of the synovial
fluid analysis.
ASSESSMENT OF PROTEASE INHIBITORS
AND LYSOSOMAL ENZYMES
The 5 protease inhibitors measured by electro-
immunoassay are listed in Table 1. Different aliquots
of 10 of the fluids were thawed and analysed by all
assays on 2 occasions separated by 6 months. Dif-
ferences were less than 10%.
The methods and results of the assays for lyso-
somal enzymes in these same fluids are detailed in
the earlier publication.2 Using 2 categories of assay,
enzymatic and immunochemical, we detected the
moieties listed in Table 2. Elastase was not detect-
able if elastin was used as a substrate (elast-1).
Cationic protein was not detectable by a radial
immunodiffusion assay (CP-2).
Table 1 Assays used to measure the protease inhibitors*
Protease inhibitor Abbreviation Lower limit of Unitst Examples of enzymes inhibited
used detectability
al-antitrypsin a1AT 3 88 %NPS Serine endopeptidases
(trypsin, elastase, collagenase)
al-antichymotrypsin ajACT 10.0 %/NPS Cationic protein$, mast cell,
and basophil chymotrypsin
a2-macroglobulin a.2M 10.0 mg/dl Most endopeptidases
Inter-a-trypsin inhibitor IaTI 10.0 %/NPS Trypsin
Cl esterase inhibitor ClLnh 7.7 %/NPS Cl (Cl esterase), plasmin, activated
Hageman factor
*All assays are electroimmunoassays as described by Laurell.14
t %/NPS is the percent of the concentration in pooled normal adult serum. Valid weight/volume standards are available for all except arACT and
IaTI. For alAT, 100%NPS = 134 mg/dl. For ClInh, 100 %/NPS= 13 mg/dl. The lower limit of detectability is given for the assay as employed.
tSee Table 2.
Table 2 Assays used to measure lysosomal enzymes
Enzyme* Abbreviation Type of assay (substrate) Lower limit of Units Reference
used detectability
Lactoferrin LF Immunochemical 0-0156 jsg/ml 1617
Myeloperoxidase MPO Immunochemical 0-0186 jLg/mi 16 17
Elastase Elast-2 Enzymatic 0.005 nk/mlt 15
(N-benzyloxycarbonyl-L
alanine 2 naphthyl ester)
Elast-3 Immunochemical 0-0041 tig/ml 18
Cationic protein CP-l Enzymatic 0.005 nk/ml 15
(2-benzyl-DL phenylalanine
2-naphthyl ester)
Lysozyme LYZ-l Enzymatic 0.087 g/ml 19
(M. lysodeikticus)
*These enzymes were readily detected in our earlier study of inflammatory synovial effusions2 using the assays listed. Several synonyms are com-
monly used. CP is also referred to as the chymotryptic-like cationic protein or cathepsin G. Lysozyme is also known as muramidase.
tNanokatals/mlr.
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DATA ANALYSIS
Because the intention of this series of investigations
is to understand the role ofPML lysosomal enzymes
in joint destruction, the synovial fluids were divided
into inflammatory and noninflammatory fluids
based solely on the absolute number of poly-
morphonuclear leucocytes (PML)/mm3. Inflam-
matory fluids have .500 PML/mm3, noninflam-
matory <500. There were 26 of the former and 6 of
the latter.
The noninflammatory group includes fluids from
4 patients with early degenerative joint disease, 1
with systemic lupus erythematosus, and 1 with
rheumatoid arthritis. The inflammatory group
included 17 fluids from rheumatoid arthritis and the
variants, and 7 from crystal deposition disease
(5 gout, 2 CPPD). The remaining 2 inflammatory
fluids were from necrotising vasculitis and systemic
lupus erythematosus.
Comparison of the 2 groups (Table 3) shows the
relative absence of radiographic destruction in the
noninflammatory group. Unlike the results for
the lysosomal enzymes,2 the inflammatory and non-
inflammatory groups are similar in the quantity of
protease inhibitor. However, most of the clinical
states represented in the noninflammatory group
do not cause erosive synovitis, nor are they likely
to have as many PML in synovial effusions. Since
our intent is to gain some insight into the reason
PML lysosomal enzymes correlate negatively with
joint destruction, the noninflammatory fluids were
excluded from the correlation analyses. The 7
crystal-induced inflammatory effusions did not
differ significantly by any of the analyses performed
on the remainder of the inflammatory fluids. The
analyses presented consider all the inflammatory
fluids together.
The data for the inflammatory fluids were sub-
jected to a correlation analysis utilising a program
written for the Hawlett-Packard 9830 computer
equipped with a 9862 plotter. The program takes a
set of data points (x,y) and calculates the coeffi-
cients of a polynomial (in this case, first degree)
using a least-squares fit. Correlation coefficients (R)
and R2 measure of fit are computed.
Results
Unlike the finding with lysosomal enzymes2 the
quantity of several protease inhibitors reflects the
total quantity of protein in the fluid (Table 4).
Since the inhibitors are synthesised principally in the
liver and all except a1AT and oc1ACT exceed albumin
in molecular weight,9 their presence in the synovial
fluid reflects the exudative nature of the effusion.20
The inhibitors similarly correlate with the number of
PML, though not as strongly as did the lysosomal
enzymes.2
However, both the lysosomal enzymes2 and the
protease inhibitors (Table 4) generally correlate
negatively with the degree of joint destruction
observed radiographically. In spite of the fact that
the protease inhibitors and lysosomal enzymes are
synthesised in different sites by different cells, they
are covariate in the inflammatory synovial effusions
(Table 5). This is striking for the lysosomal enzymes
LF and MPO, which were determined immuno-
chemically and are highly covariate with the PML/
mm32
Table 4 Correlation coefficientst for each protease
inhibitor with joint destruction and synovial fluid
characteristics
Protease inhibitor X-ray PML/ Total C3
score mm3 protein
ao-antitrypsin 0.040 0-321 0-415* 0.130
au-antichymotrypsin --0.328 0*097 0.011 0.237
a2-macroglobulin -0346 0.346 0.488* 0.073
Inter-a-trypsin inhibitor -0-569** -0-157 0.448* 0-616**
Cl esterase inhibitor -0*399 0*182 0.086 0.155
tThe level of significance of the correlation coefficients (R) is indicated
by asterisks: *=0.01<P<0.05; **=0-001<P<0-01; ***=P<
0.001.
Table 3 Comparison of the mean (I SEM) inhibitor assay values between the inflammatory and
noninflammatory fluids*
Inflammatory
Valuest Noninflammatory Total Crystal induced Noncrystal induced
Number of fluids 6 26 7 19
PML/mm3 1364136 11 648+11 594 6514±3814 13 540±12 956
Total protein (g/dl) 3*9±0*67 4-89+1*47 4-7+1*28 4-96+1*56
X-ray score 0*20+0*45 1-91+t1.57 2*20±1*79 1.82+1.55
a5-antitrypsin 56±57 100+55 123+68 87±51.
a,-antichymotrypsin 89+76 112±89 154+121 95+71
a2-macroglobulin 79+50 128+62 119+48 131+67
Inter-a-trypsin inhibitor 39 +11 52+26 65+40 49±21
Cl esterase inhibitor 186+159 246±209 269±263 238±193
*An inflammatory synovial fluid is defined as having > 500 PML/mm3. The noninflammatory fluid has < 500. tThe notations, units, and methods
for the inhibitor assays are given in Table 1.
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Table 5 Correlationi coefficients (R) between the protease inhibitors and the lysosomal enzymest
Protease inhibitors Lysosomal enzymes
LF MPO Elast-2 Elast-3 CP-I L YZ-1
a1-antitrypsin 0.561** 0.511** 0-007 0-276 0.182 0.276
a1-antichymotrypsin 0-413* 0-487* -0*016 0.160 0.199 0.332
a2-macroglobulin 0.218 0*160 0.501* 0-054 0*105 0-368
Inter-a-trypsin inhibitor 0.216 0.216 0- 518* 0.121 0.132 0.067
Cl esterase inhibitor 0-656*** 0-663*** 0.069 0.309 -0-106 0-490*
tNotations, units, and methods of determination are given for the protease inhibitors in Table 1 and lysosomal enzymes in Table 2. See Table 4
for notations of significance.
Elast-2 and CP-1 are measured enzymatically on
small synthetic substrates (Table 2) which sacrifice
specificity for high degrees of sensitivity. We pre-
viously showed that elast-2 and CP-1 values are
independent of the PML/mm3, raising the possibility
that they derive from a source other than the PML.
These enzymatic activities are not only detectable but
even correlate with the quantity of some of the
inhibitors (Table 5). Elast-2 is detectable in the
presence of an inhibitor such as oc2M because the
latter does not block access to the enzymes' active
site by low molecular weight substrates.10 No
elastase is measured if elastin is the test substrate.2
The data in Tables 4-6 are presented as univariate
correlation coefficients. This allows the reader the
option of choosing his own level of confidence in
suggesting the possibility that particular protease
inhibitors are independent. Any such inference is
testable with a larger population followed longi-
tudinally. We believe the data do not allow one to
single out any protease inhibitor as an independent
variable either by inspection of the univariate
correlation coefficients (Table 6) or by calculation
of partial correlation coefficients. Therefore the
data allows us to make the following general
assertions. Protease inhibitors in inflammatory
synovial effusions correlate with the total protein and
PML/mm3 (Table 4) and with the lysosomal enzymes
(Table 5). As we previouslyobservedforthelysosomal
enzymes,2 the quantity of these protease inhibitors
is inversely related to the degree of articular des-
truction (Table 4).
Table 6 Correlation coefficients (R) between protease
inhibitorst
ajAT auACT a2M IaTI CIINH
ajAT - 0.603** 0.307 0.063 0.375
a,ACT - 0 402* 0.385 0 - 587**
a2M - 0- 572** 0-163
IaTI - 0.276
C1INH _
tSee Table I for notations, units and methods for protease inhibitors
and Table 4 for notations of significance.
Discussion
An extensive body of data suggests that lysosomal
enzymes play a major role in articular destruction
in the erosive synovitides,2' in gout,22 and in degen-
erative joint disease.23 It is equally clear that the
cellular and tissue localisation of lysosomal cata-
bolism differs in each of these states.2' The current
studies were designed to test one long-held postulate
regarding cellular and tissue localisation of lyso-
somal degradation in rheumatoid arthritis,l namely,
that lysosomal enzymes released from PML into
synovial fluid are primarily involved in articular
destruction. At the very least this postulate has been
a landmark in stimulating productive investigation.
Certainly such enzymes have the potential to parti-
cipate in cartilage destruction.3-7 However, if it
were true, one would expect that the cumulative
quantity of active enzyme in the fluid would cor-
relate with the degree of destruction. To test such a
hypothesis in a disease with the chronicity and
variability of rheumatoid arthritis would require
longitudinal observation or single sampling of a
reasonably large population. We chose the latter
design realising that the absence of a correlation
between lysosomal enzymes and joint destruction
would be subject to considerable type 2 statistical
error.24 Our observation of a negative correlation
between the PML lysosomal enzymes and joint
destruction,2 however, casts considerable doubt on
the hypothesis.
The data reported herein provide a reasonable
explanation for the ineffectiveness of PML lyso-
somal enzymes in solution in cartilage destruction.
Inflammatory synovial fluids are replete with pro-
tease inhibitors; the inhibitors are covariate with
the lysosomal enzymes and correlate negatively
as well with joint destruction. The experiments of
Oronsky and Perper7 demonstrate in vitro the con-
siderable capacity of rheumatoid synovial fluid to
inhibit relevant human PML lysosomal hydrolases.
These observations render tenuous the hypothesis
that PML lysosomal hydrolases in solution in
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inflammatory synovial fluids participate in cartilage
degradation. They do not address the possibility of
the effectiveness of PML lysosomal hydrolases
released directly on the cartilage25 26 or of the
participation of lysosomal hydrolases with another
cellular or tissue distribution.27
There is no a-priori reason for the negative cor-
relation between joint destruction and protease
inhibitors (Table 4) and between joint destruction
and PML lysosomal enzymes2 in the synovial fluid.
This implies more than the inference that these
moieties are irrelevant to joint destruction-they
are relevant but not in the way one might predict.
We have observed a negative correlation between
C3 determined immunochemically in the effusions
and joint destruction2 but a positive correlation with
some protease inhibitors (Table 4). It appears that
there are control mechanisms modulating the several
inflammatory processes in the joint in rheumatoid
arthritis yet to be elucidated.
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